Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
0.7894
-0.0211 (-2.60%)
At close: Apr 7, 2026, 4:00 PM EDT
0.8051
+0.0157 (1.99%)
After-hours: Apr 7, 2026, 7:41 PM EDT
Heron Therapeutics Employees
Heron Therapeutics had 128 employees as of December 31, 2025. The number of employees increased by 6 or 4.92% compared to the previous year.
Employees
128
Change (1Y)
6
Growth (1Y)
4.92%
Revenue / Employee
$1,210,188
Profits / Employee
-$157,773
Market Cap
148.83M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 128 | 6 | 4.92% |
| Dec 31, 2024 | 122 | -4 | -3.17% |
| Dec 31, 2023 | 126 | -77 | -37.93% |
| Dec 31, 2022 | 203 | -99 | -32.78% |
| Dec 31, 2021 | 302 | 79 | 35.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 184 |
| Fate Therapeutics | 161 |
| Molecular Partners AG | 134 |
| Cibus | 118 |
| Immunic | 92 |
| Tenaya Therapeutics | 70 |
| Precision BioSciences | 68 |
| Spero Therapeutics | 25 |
HRTX News
- 5 weeks ago - Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 - GlobeNewsWire
- 3 months ago - Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth - GlobeNewsWire
- 4 months ago - Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) - GlobeNewsWire
- 5 months ago - Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress - GlobeNewsWire
- 5 months ago - Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors - GlobeNewsWire
- 6 months ago - Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - GlobeNewsWire
- 8 months ago - Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value - PRNewsWire